日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial

评估使用纳吉博肽抑制TREM-1治疗接受呼吸支持的COVID-19患者的疗效和安全性:ESSENTIAL随机、双盲试验

François, Bruno; Lambden, Simon; Garaud, Jean-Jacques; Derive, Marc; Grouin, Jean-Marie; Asfar, Pierre; Darreau, Cédric; Mira, Jean-Paul; Quenot, Jean-Pierre; Lemarié, Jérémie; Mercier, Emmanuelle; Lacherade, Jean-Claude; Vinsonneau, Christophe; Fivez, Tom; Helms, Julie; Badie, Julio; Levy, Mitchell; Cuvier, Valérie; Salcedo-Magguilli, Margarita; Laszlo-Pouvreau, Anne-Lise; Laterre, Pierre-François; Gibot, Sébastien

sTREM-1 is a specific biomarker of TREM-1 pathway activation

sTREM-1是TREM-1通路激活的特异性生物标志物。

Jolly, Lucie; Carrasco, Kévin; Salcedo-Magguilli, Margarita; Garaud, Jean-Jacques; Lambden, Simon; van der Poll, Tom; Mebazaa, Alexandre; Laterre, Pierre-François; Gibot, Sebastien; Boufenzer, Amir; Derive, Marc

Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial

评估纳吉博肽治疗脓毒性休克患者的疗效、安全性和耐受性的理论依据和方案(ASTONISH)IIb期随机对照试验

Francois, Bruno; Lambden, Simon; Gibot, Sebastien; Derive, Marc; Olivier, Aurelie; Cuvier, Valerie; Witte, Stephan; Grouin, Jean-Marie; Garaud, Jean Jacques; Salcedo-Magguilli, Margarita; Levy, Mitchell; Laterre, Pierre-François